Some content of this application is unavailable at the moment.
If this situation persist, please contact us atFeedback&Contact
1. (WO2018197502) T CELL REDIRECTING BISPECIFIC ANTIBODIES FOR THE TREATMENT OF EGFR POSITIVE CANCERS
Latest bibliographic data on file with the International Bureau    Submit observation

Pub. No.: WO/2018/197502 International Application No.: PCT/EP2018/060488
Publication Date: 01.11.2018 International Filing Date: 24.04.2018
IPC:
C07K 16/28 (2006.01) ,C07K 16/46 (2006.01)
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
K
PEPTIDES
16
Immunoglobulins, e.g. monoclonal or polyclonal antibodies
18
against material from animals or humans
28
against receptors, cell surface antigens or cell surface determinants
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
K
PEPTIDES
16
Immunoglobulins, e.g. monoclonal or polyclonal antibodies
46
Hybrid immunoglobulins
Applicants:
GLENMARK PHARMACEUTICALS S.A. [CH/CH]; Chemin de la Combeta 5 2300 La Chaux-de-Fonds, CH
Inventors:
LISSILAA, Rami; CH
STUTZ, Cian; CH
Agent:
THOMAS, Dean; CH
Priority Data:
17167709.924.04.2017EP
Title (EN) T CELL REDIRECTING BISPECIFIC ANTIBODIES FOR THE TREATMENT OF EGFR POSITIVE CANCERS
(FR) ANTICORPS BISPÉCIFIQUES DE REDIRECTION DE LYMPHOCYTES T POUR LE TRAITEMENT DE CANCERS POSITIFS DE L'EGFR
Abstract:
(EN) The present invention relates to bispecific antibodies which bind to CD3 and EGFR simultaneously. This class of antibody has been demonstrated by the inventors to be useful in the treatment of EGFR tumors by redirecting T cells and forming an immune synapse between activated T cells and EGFR expressing tumor cells, leading to increased levels of killing of EGFR expressing tumor cells. In particular the present invention relates to CD3xEGFR bispecific antibodies selected from the group comprising CD3xEGFR_SF1 (SEQ ID NO: 4, 5 and 6), CD3xEGFR_SF3 (SEQ ID NO: 7, 2 and 8), CD3xEGFR_SF4 (SEQ ID NO: 4, 5 and 9), CD3xEGFR_SD1 (SEQ ID 10 NO: 1, 2 and 10) and CD3xEGFR_SD2 (SEQ ID NO: 11, 10 and 2).
(FR) La présente invention concerne des anticorps bispécifiques qui se lient simultanément à CD3 et au EGFR. Il a été démontré par les inventeurs que la classe d'anticorps de la présente invention peut être utile dans le traitement de tumeurs EGFR par redirection de lymphocytes T et formation d'une synapse immunitaire entre des lymphocytes T activés et des cellules tumorales exprimant l'EGFR, conduisant à des niveaux accrus d'élimination de cellules tumorales qui expriment l'EGFR. En particulier, la présente invention concerne des anticorps bispécifiques CD3xEGFR sélectionnés dans le groupe comprenant CD3xEGFR_SF1 (SEQ ID NO : 4, 5 et 6), CD3xEGFR_SF3 (SEQ ID NO : 7, 2 et 8), CD3xEGFR_SF4 (SEQ ID NO : 4, 5 et 9), CD3xEGFR_SD1 (SEQ ID 10 NO : 1, 2 et 10) et CD3xEGFR_SD2 (SEQ ID NO : 11, 10 et 2).
front page image
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Office (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (EPO) (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG)
Publication Language: English (EN)
Filing Language: English (EN)